PA
TEVA icon

Procyon Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Procyon Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-210
Closed -$3K – 963
2020
Q2 		$3K Hold
210
– – ﹤0.01% 883
2020
Q1 		$2K Buy
+210
New +$2.15K ﹤0.01% 871

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Procyon Advisors's TEVA Position: Q3 2020 in Review

Procyon Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2020, closing a stake of 210 shares — an estimated $3K sold.

Procyon Advisors first reported a position in TEVA in Q1 2020 and held it in 2 quarters. The position peaked at $3K in Q2 2020. 443 funds tracked by Wall St. Rank hold TEVA as of Q3 2020.

  • Procyon Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Procyon Advisors sold 210 Teva Pharmaceuticals shares in Q3 2020, an estimated $3K.
  • Procyon Advisors first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Procyon Advisors's Teva Pharmaceuticals position peaked at $3K in Q2 2020.
  • 443 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.